A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hassoun, P.M. Pulmonary Arterial Hypertension. N. Engl. J. Med. 2021, 385, 2361–2376. [Google Scholar] [CrossRef] [PubMed]
- Humbert, M.; Kovacs, G.; Hoeper, M.M.; Badagliacca, R.; Berger, R.M.F.; Brida, M.; Carlsen, J.; Coats, A.J.S.; Escribano-Subias, P.; Ferrari, P.; et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2023, 61, 2200879. [Google Scholar] [CrossRef] [PubMed]
- Behr, J.; Nathan, S.D. Pulmonary hypertension in interstitial lung disease: Screening, diagnosis and treatment. Curr. Opin. Pulm. Med. 2021, 27, 396–404. [Google Scholar] [CrossRef] [PubMed]
- King, C.S.; Shlobin, O.A. The Trouble with Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. Chest 2020, 158, 1651–1664. [Google Scholar] [CrossRef] [PubMed]
- Nowak, J.; Hudzik, B.; Niedziela, J.; Rozentryt, P.; Zembala, M.; Gasior, M. Role of Pro-Brain Natriuretic Peptide Serum Concentration in the Detection of Pulmonary Hypertension in Patients with End-Stage Lung Diseases Referred for Lung Transplantation. Transplant. Proc. 2018, 50, 2044–2047. [Google Scholar] [CrossRef] [PubMed]
- Klinger, J.R. Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. Cardiol. Clin. 2016, 34, 413–433. [Google Scholar] [CrossRef] [PubMed]
- Nathan, S.D.; Barbera, J.A.; Gaine, S.P.; Harari, S.; Martinez, F.J.; Olschewski, H.; Olsson, K.M.; Peacock, A.J.; Pepke-Zaba, J.; Provencher, S.; et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur. Respir. J. 2019, 53, 1801914. [Google Scholar] [CrossRef] [PubMed]
- Waxman, A.; Restrepo-Jaramillo, R.; Thenappan, T.; Ravichandran, A.; Engel, P.; Bajwa, A.; Allen, R.; Feldman, J.; Argula, R.; Smith, P.; et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N. Engl. J. Med. 2021, 384, 325–334. [Google Scholar] [CrossRef] [PubMed]
- Lettieri, C.J.; Nathan, S.D.; Barnett, S.D.; Ahmad, S.; Shorr, A.F. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006, 129, 746–752. [Google Scholar] [CrossRef]
- Ruffenach, G.; Hong, J.; Vaillancourt, M.; Medzikovic, L.; Eghbali, M. Pulmonary hypertension secondary to pulmonary fibrosis: Clinical data, histopathology and molecular insights. Respir. Res. 2020, 21, 303. [Google Scholar] [CrossRef] [PubMed]
- Kacprzak, A.; Tomkowski, W.; Szturmowicz, M. Pulmonary Hypertension in the Course of Interstitial Lung Diseases-A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy. Diagnostics 2023, 13, 2354. [Google Scholar] [CrossRef] [PubMed]
- Idiopathic Pulmonary Fibrosis Clinical Research, N.; Zisman, D.A.; Schwarz, M.; Anstrom, K.J.; Collard, H.R.; Flaherty, K.R.; Hunninghake, G.W. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med. 2010, 363, 620–628. [Google Scholar] [CrossRef]
- Kolb, M.; Raghu, G.; Wells, A.U.; Behr, J.; Richeldi, L.; Schinzel, B.; Quaresma, M.; Stowasser, S.; Martinez, F.J.; Investigators, I. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2018, 379, 1722–1731. [Google Scholar] [CrossRef]
- Behr, J.; Nathan, S.D.; Wuyts, W.A.; Mogulkoc Bishop, N.; Bouros, D.E.; Antoniou, K.; Guiot, J.; Kramer, M.R.; Kirchgaessler, K.U.; Bengus, M.; et al. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2021, 9, 85–95. [Google Scholar] [CrossRef]
- Raghu, G.; Behr, J.; Brown, K.K.; Egan, J.J.; Kawut, S.M.; Flaherty, K.R.; Martinez, F.J.; Nathan, S.D.; Wells, A.U.; Collard, H.R.; et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: A parallel, randomized trial. Ann. Intern. Med. 2013, 158, 641–649. [Google Scholar] [CrossRef]
- Nathan, S.D.; Behr, J.; Collard, H.R.; Cottin, V.; Hoeper, M.M.; Martinez, F.J.; Corte, T.J.; Keogh, A.M.; Leuchte, H.; Mogulkoc, N.; et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): A randomised, placebo-controlled phase 2b study. Lancet Respir. Med. 2019, 7, 780–790. [Google Scholar] [CrossRef] [PubMed]
- Whittle, B.J.; Silverstein, A.M.; Mottola, D.M.; Clapp, L.H. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist. Biochem. Pharmacol. 2012, 84, 68–75. [Google Scholar] [CrossRef] [PubMed]
- Waxman, A.; Restrepo-Jaramillo, R.; Thenappan, T.; Engel, P.; Bajwa, A.; Ravichandran, A.; Feldman, J.; Hajari Case, A.; Argula, R.G.; Tapson, V.; et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. Eur. Respir. J. 2023, 61, 2202414. [Google Scholar] [CrossRef] [PubMed]
- Faria-Urbina, M.; Oliveira, R.K.F.; Agarwal, M.; Waxman, A.B. Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease. Lung 2018, 196, 139–146. [Google Scholar] [CrossRef] [PubMed]
- Olschewski, H.; Ghofrani, H.A.; Walmrath, D.; Schermuly, R.; Temmesfeld-Wollbruck, B.; Grimminger, F.; Seeger, W. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999, 160, 600–607. [Google Scholar] [CrossRef] [PubMed]
March 2023 | July 2023 | October 2023 | January 2024 | |
---|---|---|---|---|
LVEF, % | 61 | 56 | 58 | 62 |
TAPSE, mm | 11 | 11.3 | 11.8 | 12.8 |
TR Vmax, m/s | 4.2 | 3.81 | 4.25 | 3.44 |
PG (RV–RA), mmHg | 70.6 | 58.1 | 72.3 | 47.3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jang, J.H.; Jang, H.-J.; Lee, J.H. A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost. Life 2024, 14, 1068. https://doi.org/10.3390/life14091068
Jang JH, Jang H-J, Lee JH. A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost. Life. 2024; 14(9):1068. https://doi.org/10.3390/life14091068
Chicago/Turabian StyleJang, Ji Hoon, Hang-Jea Jang, and Jae Ha Lee. 2024. "A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost" Life 14, no. 9: 1068. https://doi.org/10.3390/life14091068